Furthermore, based on the closed correlation between excessive fructose intake, insulin resistance, and NAFLD, several studies indicated that metformin, an AMPK activator, might have therapeutic potential on liver steatosis [30]. This evidence concerns the gene PRKAA1 and fatty liver disease.